Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14376 - 14400 of 14618 in total
Ammonium molybdate is a source of molybdenum that exists in several hydrate forms. It is intravenously administered as an additive to solutions for Total Parenteral Nutrition (TPN). Molybdenum is an essential element that is present in enzymes including xanthine oxidase, sulfite oxidase, and aldehyde oxidase.
Experimental
Matched Description: … Molybdenum is an essential element that is present in enzymes including xanthine oxidase, sulfite oxidase, and
Cyclopropane was initially investigated because it was thought to be the toxic element in ethylene. Instead, it turned out to be an excellent anesthetic with very rapid onset and recovery while maintaining stable hemodynamics. Its use was ultimately limited because it was highly explosive.
Experimental
Matched Description: … Instead, it turned out to be an excellent anesthetic with very rapid onset and recovery while maintaining …
Lortalamine (LM-1404) is a selective norepinephrine reuptake inhibitor developed in the 1980s. This drug never made it past clinical trials, likely due to ocular toxicity in animals, but has been used in positron emission tomography studies to label norepinephrine transporters.
Experimental
T-62 has been used in trials studying the treatment of Postherpetic Neuralgia.
Investigational
Roluperidone has been used in trials studying the treatment of Schizophrenia.
Investigational
Investigational
Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.
Investigational
Iguratimod is under investigation in Rheumatoid Arthritis.
Investigational
CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been...
Investigational
Matched Description: … lipid profiles, and this dose has proven to be well tolerated in clinical trials. ... in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and
Experimental
Illicit
Displaying drugs 14376 - 14400 of 14618 in total